Author | Mean follow-up (years) | Immediate AT prevalence (%) (<30 days) | Mid-term AT prevalence (%) (>30 days–5 years) | Late AT prevalence (%) (>5 years) |
Taniguchi et al13 | 0.9 | NS | 100 | NS |
Giardini et al14 | 4.8 | 6.0 | 3.7 | NS |
Wilson et al15 | 1.8 | NS | 5.0 | NS |
Spies et al16 | 0.5 | 22.1 | NS | NS |
Silversides et al‡ 17 | 1.9 | NS | 6.5 | NS |
Silversides et al† 18 | 1.4 | 15.0 | 8.3 | NS |
Suarez de Lezo et al19 | 0.7 | 7.1 | 7.1 | NS |
Erkut et al20 | 4.2 | 12.2 | 12.2 | NS |
Piechowiak et al21 | 6.6 | 23.7 | NS | 23.7 |
Mantovan et al22 | 5.7 | NS | NS | 7.4 |
Ghosh et al23 | 4.7 | NS | 18.0 | NS |
Donti et al24 | 9 | NS | NS | 26.4 |
Jemielity et al25 | 6.9 | NS | NS | 5.3 |
Gatzoulis et al7 | 3.8 | 13.1 | 11.3 | NS |
Berger et al2 | NS | 21.3 | NS | NS |
Shibata et al26 | 9.7 | 40.8 | NS | 32.7 |
Konstantinides et al27 | 8.9 | NS | NS | 26.2 |
Shah et al28 | 25.0 | NS | NS | 25.0 |
Speechly-Dick et al29 | 2* | 10.9 | 10.9 | NS |
Murphy et al4 | 27.2 | NS | NS | 10.6 |
Cowen et al30 | 3.0 | 38.7 | NS | NS |
Brandenburg et al31 | 12 | 4.8 | NS | 10.6 |
Lomholt et al32 | 3.7 | NS | 21.4 | NS |
Esscher et al33 | 12 | 5.4 | NS | 5.4 |
Saksena et al34 | 6 | 45.8 | NS | 45.8 |
Aldridge and Yao35 | NS | 12.8 | NS | NS |